Promising Phase 1/2 Results for ACELYRIN's Lonigutamab Support Buy Rating
Derek Archila, an analyst from Wells Fargo, maintained the Buy rating on ACELYRIN, INC. (SLRN – Research Report). The associated price target remains the same with $13.00.
Derek Archila’s rating is based on the promising updates from ACELYRIN, INC.’s Lonigutamab (loni) Phase 1/2 trial. The data suggests that loni shows sufficient activity to advance to Phase 3 trials, with potential safety advantages over competitors. This advancement is seen as a strategic opportunity for long-term investors, especially with the stock trading significantly below cash value.
Furthermore, the efficacy of loni in its 12-week regimen appears comparable to other treatments like Veligrotug and Tepezza, despite a small patient sample size. The Phase 3 regimen aims to increase drug exposure, potentially enhancing efficacy. Additionally, loni’s safety profile is competitive, with no dose-dependent adverse events, reducing concerns about safety in future trials. These factors collectively support the Buy rating for ACELYRIN, INC.’s stock.
In another report released today, Piper Sandler also reiterated a Buy rating on the stock with a $20.00 price target.
ACELYRIN, INC. (SLRN) Company Description: Acelyrin, Inc., a clinical biopharma company, focuses on identifying, acquiring, and accelerating the development and commercialization of transformative medicines. The company’s lead product candidate is izokibep, a small protein therapeutic designed to inhibit IL-17A with high potency, which is in Phase 3 clinical trials for use in the treatment of Hidradenitis Suppurativa, Psoriatic Arthritis, and uveitis, as well as in Phase 2 clinical trials for use in the treatment of Axial Spondyloarthritis. It is also developing lonigutamab, a humanized immunoglobulin G1 (IgG1) monoclonal antibody against insulin-like growth factor 1 receptor, which is in Phase 1 clinical trials for use in the treatment of thyroid eye disease; and SLRN-517, a fully human IgG1 monoclonal antibody targeting c-KIT, which is in preclinical stage for use in the treatment of chronic urticaria. The company was incorporated in 2020 and is headquartered in Agoura Hills, California.